chevron_leftBack
As of 13 June 2026, Inhibrx Biosciences, Inc. has a market cap of $1.82B USD, ranking #7488 globally and #1760 in the United States.
It ranks #606 in the Healthcare sector, and #113 in the Biotechnology industry.
Key Stats
Market Cap
$1.82BUSD
Enterprise Value
$1.82BUSD
Revenue (TTM)
$1.3MUSD
EBITDA (TTM)
-$132.54MUSD
Net Income (TTM)
-$140.06MUSD
PS Ratio
1412.7
PB Ratio
238.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Lappe
open_in_new
Employees
110
Founded
2010
IPO
19 Aug 2020
Website
inhibrx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.5% | 8.6% | 114% | 69% | 83% | 912% |
News
Loading...
INBX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
INBX
Inhibrx Biosciences Inc
ISIN: US45720N1037
Shares Out.:
Shares Outstanding:
14.671M1
Shares Float:
10.868M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
124.82 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
10K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
9K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
1K%
|
-
|
|
NYSE: IQV
|
$26.3B
1K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
1K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
894%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
3K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
2K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
2K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
2K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
1K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
1K%
|
-
|
chevron_leftBack